Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Enliven Therapeutics (ELVN) Accumulated Depreciation & Amortization (2019 - 2026)

Enliven Therapeutics has reported Accumulated Depreciation & Amortization over the past 8 years, most recently at $14000.0 for Q1 2026.

  • Quarterly results put Accumulated Depreciation & Amortization at $14000.0 for Q1 2026, down 81.08% from a year ago — trailing twelve months through Mar 2026 was $14000.0 (down 81.08% YoY), and the annual figure for FY2025 was $300000.0, changed 0.0%.
  • Accumulated Depreciation & Amortization reached $14000.0 in Q1 2026 per ELVN's latest filing, down from $300000.0 in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $39.0 million in Q1 2022 and bottomed at $14000.0 in Q1 2026.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $151000.0 (2022), compared with a mean of $2.4 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization crashed 99.83% in 2023 before it skyrocketed 171.25% in 2025.
  • Over 5 years, Accumulated Depreciation & Amortization stood at $200000.0 in 2022, then surged by 50.0% to $300000.0 in 2023, then changed by 0.0% to $300000.0 in 2024, then changed by 0.0% to $300000.0 in 2025, then plummeted by 95.33% to $14000.0 in 2026.
  • Business Quant data shows Accumulated Depreciation & Amortization for ELVN at $14000.0 in Q1 2026, $300000.0 in Q4 2025, and $217000.0 in Q3 2025.